

Index

Note: Page numbers in *italics* refer to figures, those in **bold** refer to tables and boxes

- advanced disease 20
- anaemia 8
- analgesia
 - bone pain 50
 - radiotherapy side-effects 39
- analgesic ladder 39
- antibiotics, prophylactic during chemotherapy 24
- antitussives 49
- anxiolytics 49
- asbestos 3, 4
 - exposure history 6
 - mesothelioma 25
 - use 25–6
- Asia, epidemiological trends 2
- Australasia, epidemiological trends 2
- bias in screening 45, 46
- biomarkers 46–7
- biopsy
 - bronchial epithelium cells 47
 - CT-guided needle **16**, 17, 29
 - fine-needle transthoracic 9
 - image-guided 18
 - mesothelioma
 - diagnosis 27
 - spread 26
 - non-small cell lung cancer 29
 - ultrasound **16**
- bisphosphonates 50
- blood tests 8–9
- bone metastases 50, 51
- bone pain 7, 50
- brain metastases 7, 42, 50
 - from small-cell lung cancer 23
- breathing
 - efficient 49
 - laboured 8
- breathlessness 7, 8
 - management 48–9
 - mesothelioma
 - management 27
 - presentation 26
- British Thoracic Society (BTS) guidelines 31
- bronchial epithelium cells 47
- bronchoalveolar cell carcinoma (BAC) 3
- bronchoscopy
 - fibreoptic 9, **16**, 17, 19
 - specimens 47
- brushings, bronchial epithelium cells 47
- cachexia 8
- cachexia–anorexia syndrome 49
- cancer types 15
- carbon monoxide transfer factor (TLCO) **33**, 37
- carboplatin, small cell lung cancer 22
- cardiopulmonary exercise tests **33**
- chemoradiotherapy 37, 42–3
 - concurrent 42–3
 - sequential 42
 - small cell lung cancer 23
- chemotherapy
 - adjuvant 41
 - mesothelioma 28
 - adverse effects 20–21
 - brain metastases 50
 - mesothelioma 27–8
 - neoadjuvant 40–41, 41–2
 - postoperative 41
 - preoperative 40–41, 41–2
 - primary for locally advanced NSCLC 43
 - second-line 24
 - small cell lung cancer 22–4, 29
 - superior vena cava obstruction 50
 - surgery combination 40–42
- chest drain, mesothelioma spread 27
- chest infection
 - chemotherapy adverse effect 24
 - mesothelioma differential diagnosis 26
- chest pain 7
- chest physiotherapy 35
- chest radiography 8, 9, 15–16, 17
 - diagnostic pathway 11
 - mesothelioma 26, 27
 - diagnosis 27
 - screening 44–5
 - surgery 31, 34
- chest wall mass, mesothelioma presentation 26
- chronic obstructive pulmonary disease 8
 - cancer risk 4
 - follow-up 14
 - susceptibility of women 4
- cigar smoking
- cigarette smoking
 - lifetime risk 2
 - susceptibility of women to lung cancer 4
 - UK 1
- cisplatin 22
- clinical examination 7–8
- clinical trials, screening methods 44–6
- codeine 49
- combination therapies 40–43
- computed tomography (CT) scanning 9, **16**, 17, 18, 20
 - low-dose 45–6, 47
 - mesothelioma diagnosis 26–7
 - PET combined 17–18, 19, 20, 37
 - planning 37
 - staging 11–12
- confusion 7
- continuous hyperfractionated accelerated radiotherapy (CHART) 36, 37
- cough 7
 - management 49
 - mesothelioma presentation 26
 - radiotherapy side-effects 38, 39
- curative treatment, goal 17–20
- cyclophosphamide 22, 23
- depressive illness 50
- dexamethasone 50
- diagnosis of lung cancer 7, 12, 13
 - tissue 20
- diagnostic delays 9
- diagnostic pathways 9, 11–12, 13, 14
- Doll and Hill study 2, 3
- domperidone 23
- doxorubicin 22, 23
- dying 52
- dyspnoea 7
- EEMMA symptom management 48
- electric fans 49
- epidemiological trends 1–2
- epirubicin 22
- etoposide 22, 23
- European Union (EU) countries
 - epidemiological trends 1–2, 3
 - geographical variations in surgery **29**
 - mesothelioma death rate 25
- expectorants 49
- extrapleural pneumonectomy (EPP) 28
- extrathoracic spread 7

- fatality, definition 45
 fatigue management 49
 fine-needle biopsy, transthoracic 9
 finger clubbing 8
 fits 7
 18F-fluorodeoxyglucose 12, 13, 17–18
 follow-up 14
 forced expiratory volume in the first second (FEV₁) 31
 forced vital capacity (FVC) 31
 Framework Convention on Tobacco Control (WHO) 4
- gender
 epidemiological trends 1, 2, 3
 susceptibility 4
 Gold Standards Framework 52
 government actions 4
 granisetron 23
 gross tumour volume (GTV) 37
- haemoptysis 7
 palliative radiotherapy 39
 hair loss, chemotherapy adverse effect 23
 headache 7
 hepatomegaly 8
 high-dependency unit (HDU) 35
 hilar lymph node involvement 42
 hypercalcaemia 50
- ifosfamide 22, 23
 imaging techniques 15–17
 immunosuppression, chemotherapy adverse effect 23
 intracranial pressure, raised 8
 investigations 8–9
 primary care 11
 secondary care 11–12
- key workers 14
- lactate dehydrogenase, serum levels 21, 22
 last days of life 52
 lethargy, radiotherapy side-effects 38
 linear accelerator (LINAC) 36
 Liverpool Care of the Dying Pathway 52
 lobectomy 31, 34
 locally advanced disease,
 chemoradiotherapy 42–3
 loss, psychological response 51, 52
 lung cancer nurse specialist 14
 lung consolidation 8
 lung fibrosis, radiotherapy late side-effects 39
 lung function tests
 fitness for surgery 31
 prior to radiotherapy 37
 lung lobes 33
 lung resection with chest wall resection 34
 lymph nodes
 involvement 17
 non-small cell lung cancer 30
- magnetic resonance imaging (MRI) 16, 20
 malignant pleural mesothelioma 25–8
 Mayo Lung Project 45
 mediastinal lymph nodes, spread 19
 mediastinoscopy 16, 19–20
- mesothelin 28
 mesothelioma, malignant pleural 25–8
 chemotherapy 27–8
 death rate 25
 diagnosis 26–7
 management strategy 27
 palliative care 27
 presenting features 26
 screening 28
 supportive care 27
 metastases 7, 17
 bone 50, 51
 brain 7, 23, 42, 50
 cerebral 7
 detection 18
 non-small cell lung cancer 30
 signs 8
 spinal cord compression 50, 51
 metoclopramide 23
 midazolam 49
 minimally invasive thoroscopic
 resection 34–5
 morphine 49
 mortality, definition 45
 mortality rate, UK 1, 2
 mucositis, chemotherapy adverse effect 24
 multidisciplinary team 9, 12, 13, 14
 mesothelioma referral 27
 multileaf collimator (MLC) 37, 38
 myelitis, radiation 24, 39
- National Institute for Clinical Excellence (NICE)
 radiotherapy guidelines 36
 referral guidance 8, 11, 12
 nausea, chemotherapy adverse effect 23
 needle aspiration, mesothelioma spread 26, 27
 needle biopsy, CT-guided 16, 17
 nicotine, addictiveness 4
 non-small cell lung cancer (NSCLC) 11, 15
 chemotherapy
 adjuvant 41
 neoadjuvant 41–2
 primary 43
 diagnosis 29
 early-stage disease 40
 lymph nodes 30
 mediastinoscopy 19
 metastases 30
 radiotherapy 36–9
 staging 15, 30–31
 surgery 29–35
 survival 31, 40, 41
 TNM staging 31
- oat cell carcinoma 21
 occupational exposure
 asbestos 3
 risk 6
 oesophagitis
 chemotherapy adverse effect 24
 radiotherapy side-effects 38, 39
 opioids 49
 analgesia 39
 outcome measures 45
 oxygen saturation 33
- pack years of consumption estimation 7
 pain
 bone 7, 50
 chest 7
 post-surgical management 35
 palliative care 49–52
 key worker 14
 last days of life 52
 mesothelioma 27
 pleural effusion 49
 primary care 52
 relatives 51
 spirituality 51
 superior vena cava obstruction 49–50
 palliative therapy 20
 goal 17–20
 radiotherapy 24, 39
 planning 38
 paravertebral anaesthesia 35
 passive smoking 3, 4
 patient-controlled analgesia (PCA) 35
 pemetrexed 27–8
 performance status, small cell lung cancer 21, 22
 peripheral nerves, chemotherapy adverse effect 24
 physiotherapy 35
 pipe smoking 2
 planning target volume (PTV) 37, 38
 platinum regimens 22–3
 pleural effusion 8
 follow-up 14
 palliative care 49
 pleural fluid aspiration 26
 pleurectomy/decortication (P/D) 28
 pleurodesis 27
 pneumonectomy 31–2
 air-fluid levels 32, 34
 chest X-ray after 34
 extrapleural 28
 pneumonitis, radiotherapy late side-effects 39
 positron emission tomography (PET) 12, 13, 16, 17–18, 19
 CT combined 17–18, 19, 20, 37
 postoperative radiotherapy (PORT) 40
 prevention of lung cancer 4
 primary care
 investigations 11
 management 52
 prognosis 15
 prophylactic cranial irradiation (PCI) 23
 psychological aspects of terminal illness 50–51
 pulmonary nodule, solitary/indeterminate 34–5
 pulmonary resection, standard major 31–2
- racial factors 2
 radiation myelitis, radiotherapy late side-effects 24, 39
 radical radiotherapy 20
 planning 37, 38
 side-effects 39
 radiobiology of tumours 36–7
 radiotherapy
 bone pain 50
 hemithorax for mesothelioma 28
 late side-effects 38–9
 mechanism of action 36
 non-small cell lung cancer 36–9

- outcomes 39
- palliative 24, 39
 - planning 38
- patient positioning 37
- radical 20
 - planning 37, 38
 - side-effects 39
- side-effects 24, 36, 38–9
 - treatment 39
- spinal cord
 - compression 50
 - inflammation 24
- superior vena cava obstruction 50
- surgery combination 40
 - see also* chemoradiotherapy
- radon 3–4
- referral 11
 - diagnosis 9
 - guidance 8, 11, 12
- relatives
 - care 51
 - last days of life care 52
 - psychological distress 51, 52
- relaxation therapies 49
- respiratory symptoms 6

- screening 44–7
 - bias 45, 46
 - clinical trials 44–6
 - low-dose CT 45–6, 47
 - mesothelioma 28
 - programmes 44
- secondary care, investigations 11–12
- segmentectomy 33
- selective serotonin reuptake inhibitors (SSRIs) 49
- skin erythema, radiotherapy side-effects 38
- small cell lung cancer (SCLC) 15, 21–4
 - brain metastases 23
 - chemotherapy 22–4, 29
 - classification 21
 - follow-up 24
 - investigations 21–2
 - paraneoplastic syndromes 21
 - prognosis 22
 - prognostic factors 21, 22
 - staging 15, 21
 - treatment 22, 29

- smoking, passive 3, 4
- smoking cessation programmes 4
- socioeconomic factors 1, 2
- specialist cancer nurse 14
- spinal cord
 - compression 50, 51
 - radiation-induced inflammation 24, 39
- spirituality 51
- spirometry 9
 - abnormal 7
 - fitness for surgery 31
- spontaneous disease 3
- sputum cytology 9
 - bronchial epithelium cells 47
 - screening 44–5
- staging 11–12, 15, 20
 - see also* tumour node metastasis (TNM) staging
- stents, superior vena cava obstruction 50
- steroids 23, 50
- sublobar resection 32–3
- superior vena cava obstruction 8, 22
 - palliative care 49–50
- supportive care 48–50
- supraclavicular lymphadenopathy 8
- surgery 20
 - brain metastases 50
 - chemotherapy combination 40–42
 - chest X-ray 31, 34
 - classification of lung cancer suitability 29
 - extended resection 33–4
 - fitness for 31
 - full assessment 31
 - geographical variations 29
 - initial assessment 31
 - mesothelioma 28
 - minimally invasive thoroscopic resection 34–5
 - non-small cell lung cancer 29–35
 - patient selection algorithm 32
 - postoperative care 35
 - procedure choice 31
 - radiotherapy combination 40
 - standard major pulmonary resection 31–2
 - sublobar resection 32–3
 - workup in potentially curable patients 33
 - see also* video-assisted thoroscopic surgery (VATS)

- survival, definition 45
- survival rate, UK 1, 2
- symptoms
 - identifying patients at risk 6
 - management 48–50
 - presenting 6–7

- talc pleurodesis 27
- taxanes 22
- terminal illness, psychological aspects 50–51
- thoracic epidural anaesthesia 35
- thoracotomy 29, 31, 33
- tiredness, radiotherapy side-effects 38
- treatment plan 20
- tumour control probability (TCP) 36
- tumour node metastasis (TNM) staging 15, 16, 17
 - non-small cell lung cancer 30–31, 31
- tumour radiobiology 36–7

- UK
 - epidemiological trends 1, 2
 - geographical variations in surgery 29
 - mesothelioma death rate 25, 26
 - primary prevention 4
- ultrasound 16, 20
- ultrasound-guided interventions 20
- USA
 - epidemiological trends 2
 - geographical variations in surgery 29
 - mesothelioma death rate 25

- ventilation/perfusion (V/Q) scan 33
- video-assisted thoroscopic surgery (VATS)
 - keyhole 34–5
 - mesothelioma diagnosis 27, 28
- vinca alkaloids 22, 23
- vomiting, chemotherapy adverse effect 23

- wedge resection 32–3, 35
- weight loss 7
 - management 49
- World Health Organisation (WHO)
 - analgesic ladder 39
 - Framework Convention on Tobacco Control 4
 - performance status in small cell lung cancer 21, 22

